Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06308081 · ClinicalTrials.gov registry record · NA
Social Media Anti-Vaping Messages to Reduce ENDS Use Among Sexual and Gender Minority Teens
A NA study, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- NA
- Development phase
- 1,155
- Enrollment target
NCT06308081 is a NA study that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 1,155 participants.
The verdict
NCT06308081, a NA study, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,155 participants
- Enrollment target
Study Summary
The investigators long-term goal is to reduce tobacco use and tobacco-related health disparities among SGM populations. The objective of Project SMART (Social Media Anti-Vaping Messages to Reduce ENDS Use Among Sexual and Gender Minority Teens) is to evaluate the effectiveness of an sexual gender minority (SGM) -tailored social media intervention to prevent vaping initiation among SGM youth ages 13-20 years. The investigators central hypothesis is that SGM-tailored anti-vaping social media messages will be more effective than existing non-tailored messages to prevent vaping initiation among SGM youth. The scientific premise for this work is based on principles of cultural tailoring in health communication for vulnerable populations, the Health Equity Promotion Model, and the Message Impact Framework. The investigators are developing and evaluating a social media intervention because SGM youth have a high rate of social media use and are more likely to go online for health information than non-SGM youth. Social media, moreover, are increasingly used for health promotion to address health disparities and well-being of SGM populations. The investigators will conduct rapid-cycle feedback with stakeholders including SGM organization leaders to provide input on the message design, testing, and intervention implementation to ensure feasibility and acceptability of the intervention.
Interventions
- OTHER Tailored
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,155 participants |
| Start Date | 2024-02-21 |
| Est. Completion | 2025-08-15 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06308081
The ClinicalTrials.gov registry entry for NCT06308081 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 1,155 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tailored is the first listed.
NCT06308081 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06308081 about?
NCT06308081 is a clinical study titled "Social Media Anti-Vaping Messages to Reduce ENDS Use Among Sexual and Gender Minority Teens". The investigators long-term goal is to reduce tobacco use and tobacco-related health disparities among SGM populations. The objective of Project SMART (Social Media Anti-Vaping Messages to Reduce ENDS Use Among Sexual and Gender Minority Teens) is to evaluate the effectiveness of an sexual gender mi...
What is the current status of trial NCT06308081?
This trial is currently completed. It is a NA study. The enrollment target is 1,155 participants. The study started on 2024-02-21. Estimated completion is 2025-08-15.
What interventions are being tested in trial NCT06308081?
The interventions under investigation include: Tailored (OTHER).
Who is sponsoring clinical trial NCT06308081?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.